Want to see GB:IMM full AI Analyst Report?
IMM Stock Chart & Stats
3.50 p
-0.48 p(-10.67%)
At close: 4:00 PM EDT
3.50 p
-0.48 p(-10.67%)
Day’s Range― - ―
52-Week Range3.30 p - 19.40 p
Previous CloseN/A
Volume1.18M
Average Volume (3M)1.63M
Market Cap
£22.46M
Enterprise Value18.98M
Total Cash (Recent Filing)£1.35M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield17.86%
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding623,911,400
10 Day Avg. Volume1,756,593
30 Day Avg. Volume1,634,680
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)44.28
Price to Sales (P/S)0.00
P/FCF Ratio-12.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Minimal Debt BurdenVery low leverage reduces interest obligations and refinancing exposure, giving ImmuPharma greater financial flexibility while it advances its pipeline. This is a durable balance-sheet advantage, although it does not offset the need for external funding.
Narrowing LossesThe smaller annual loss suggests some operating-cost discipline and could help preserve cash if sustained. However, losses remain material and, without revenue, this improvement does not yet establish a self-funding or commercially proven model.
Focused Clinical PipelineA focused clinical-stage model can concentrate ImmuPharma’s limited resources on autoimmune and inflammatory programs, creating longer-term pipeline optionality. The opportunity is structurally meaningful, though it remains dependent on clinical and regulatory execution.
Bears Say
No Recent RevenueThe absence of recent revenue shows that ImmuPharma has not yet commercialized a product or established recurring operating income. This leaves results dependent on pipeline progress and financing rather than customer demand, increasing execution risk over the medium term.
Persistent Cash BurnContinued negative operating and free cash flow means the business consumes cash to maintain operations and advance development. Unless the operating model changes or assets are partnered, recurring external funding will remain important to sustain the pipeline.
Fragile Equity BaseThe swing from negative to positive equity indicates a thin and volatile capital base relative to ongoing losses. This weakens financial resilience and may constrain strategic flexibility, particularly because the company lacks established revenue to absorb development costs.
ImmuPharma News
IMM FAQ
What was ImmuPharma PLC’s price range in the past 12 months?
ImmuPharma PLC lowest share price was 3.30 p and its highest was 19.40 p in the past 12 months.
What is ImmuPharma PLC’s market cap?
ImmuPharma PLC’s market cap is £22.46M.
When is ImmuPharma PLC’s upcoming earnings report date?
ImmuPharma PLC’s upcoming earnings report date is Sep 24, 2026 which is in 16 days.
How were ImmuPharma PLC’s earnings last quarter?
ImmuPharma PLC released its earnings results on May 27, 2026. The company reported 0 p earnings per share for the quarter.
Is ImmuPharma PLC overvalued?
According to Wall Street analysts ImmuPharma PLC’s price is currently Overvalued.
Does ImmuPharma PLC pay dividends?
ImmuPharma PLC pays a Notavailable dividend of 1 p which represents an annual dividend yield of 17.86%. See more information on ImmuPharma PLC dividends here
What is ImmuPharma PLC’s EPS estimate?
ImmuPharma PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImmuPharma PLC have?
ImmuPharma PLC has 623,911,400 shares outstanding.
What happened to ImmuPharma PLC’s price movement after its last earnings report?
ImmuPharma PLC reported an EPS of 0 p in its last earnings report. Following the earnings report the stock price went down -4.333%.
Which hedge fund is a major shareholder of ImmuPharma PLC?
Currently, no hedge funds are holding shares in GB:IMM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ImmuPharma PLC
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company’s lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140, which is in Phase II clinical trial for the treatment of chronic inflammatory demyelinating polyneuropathy, a rare acquired autoimmune disorder of peripheral nerve; and P140 that covers other indications acute and chronic asthma, gout, irritable bowel disease, and periodontitis. Its pre-clinical products include BioAMB, a peptide-based drug of Amphotericin-B formulations for the treatment of serious and life-threatening fungal infections, such as aspergillosis; and BioCin, a vancomycin based treatment for anti-infection. It has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of 1P40 platform; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
Technical Analysis
Sareum Holdings
―
Scancell Holdings
―
HemoGenyx Pharmaceuticals Plc
―
SkinBioTherapeutics
―
Poolbeg Pharma Ltd.
―